Neuroblastoma is a common and lethal pediatric malignancy, but the genetic events that initiate tumorigenesis are largely unknown. We hypothesize that neuroblastoma is a complex disease that results from the interaction of mutant alleles with relatively low to moderate effect on tumor initiation. We now plan to discover neuroblastoma susceptibility genes by performing a definitive whole genome association study in ~5000 neuroblastoma patients from the Children's Oncology Group using a high-density single nucleotide polymorphism (SNP)-based replicative study design. We will compare our cases to two control sets: both pediatric non-cancer patients accessioned from our institution, and adult control subjects matched by region across the country. We propose four Specific Aims: First, we will perform a whole genome scan for association of neuroblastoma with SNPs and SNP haplotypes in 2000 neuroblastoma cases and an equal number of matched controls (both children and adults in parallel analyses). Over 550K SNPs will be surveyed, and we anticipate identifying 25,000-50,000 candidate SNPs for further evaluation. Second, we will identify true disease-associated SNP alleles using a customized genotyping platform enriched for haplotype analyses in an independent set of 2000 cases and again two large control sets. By leveraging the HapMap project and controlling for population substructure, we anticipate that this Aim will identify 10-20 genomic regions as candidates for association with neuroblastoma. Third, we will validate at least 5-10 disease-associated regions in a final independent sample set of 675 cases and two sets of ~675 controls. We will again use a gene-centric haplotyping approach to determine true disease associated variants and candidate genes. Finally, we will definitively identify neuroblastoma predisposition genes through direct resequencing of candidate regions in a carefully selected set of 100 neuroblastoma cases and 100 controls, each equally proportioned between the presence or absence of the SNP/haplotype variant associated with neuroblastoma. Our large panel of tumor reagents and genomics databases will be leveraged to assist in region prioritization and identification of candidate genes for further analysis. The successful completion of this project will provide insight into the underlying genetic etiology of neuroblastoma tumorigenesis. We ultimately plan to translate the discovered neuroblastoma predisposition genes into a prognostic biomarkers and/or a target for new treatment approaches. In addition, the data generated here will rapidly be made available to any academically qualified petitioner interested in associating the SNP genotypes with the robust phenotypic information that we have captured including clinical characteristics, tumor biology, response to therapy and disease outcome. Finally, this project should also help catalyze the field of childhood cancer applied genomics research, and if past lessons from other childhood cancers are repeated, it will identify genes that are fundamentally important in human cancer in general.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA124709-05
Application #
8213485
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Zanetti, Krista A
Project Start
2008-04-01
Project End
2013-03-31
Budget Start
2012-02-01
Budget End
2013-03-31
Support Year
5
Fiscal Year
2012
Total Cost
$602,864
Indirect Cost
$217,646
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Cimmino, Flora; Avitabile, Marianna; Diskin, Sharon J et al. (2018) Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. Int J Cancer 143:2828-2837
Zhu, Shizhen; Zhang, Xiaoling; Weichert-Leahey, Nina et al. (2017) LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell 32:310-323.e5
Tolbert, Vanessa P; Coggins, Grace E; Maris, John M (2017) Genetic susceptibility to neuroblastoma. Curr Opin Genet Dev 42:81-90
Harenza, Jo Lynne; Diamond, Maura A; Adams, Rebecca N et al. (2017) Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci Data 4:170183
Chang, Xiao; Zhao, Yan; Hou, Cuiping et al. (2017) Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk. Nat Commun 8:569
Harenza, Jo Lynne; Diamond, Maura A; Adams, Rebecca N et al. (2017) Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci Data 4:170033
Applebaum, Mark A; Vaksman, Zalman; Lee, Sang Mee et al. (2017) Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer 72:177-185
Mazul, Angela L; Siega-Riz, Anna Maria; Weinberg, Clarice R et al. (2016) A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group. Cancer Causes Control 27:1209-18
Walsh, Kyle M; Whitehead, Todd P; de Smith, Adam J et al. (2016) Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. Carcinogenesis 37:576-582
Bosse, Kristopher R; Maris, John M (2016) Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 122:20-33

Showing the most recent 10 out of 33 publications